-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Spinal muscular atrophy (SMA) is a type of disease in which muscle weakness and muscle atrophy are caused by the degeneration of motor neurons in the anterior horn of the spinal cord
Spinal muscular atrophy (SMA) is a type of disease in which muscle weakness and muscle atrophy are caused by the degeneration of motor neurons in the anterior horn of the spinal cord
This method aims to economically evaluate the short-term and long-term cost-effectiveness of early identification of SMA through modified disease therapy (ie, nusinersen or gene therapy), which is mainly compared with unscreened nusinersen therapy and previously unscreened and supported by care Case comparison
A series of Markov cohort simulations were conducted to reflect the health outcomes and costs of each infant in the population: (1) NBS that uses nusinersen for early identification and treatment (2) NBS can identify and initiate gene therapy early (3) Pass Clinical referral for symptom diagnosis, and treatment with nusinersen from the time of diagnosis and (4) symptom diagnosis through clinical referral, and management by supportive care
SMA NBS Decision Analysis Model
The parameters of the decision analysis model come from laboratory data from the New South Wales/Australian Capital Territory National Bureau of Statistics pilot project
Markov queue simulation is a random process that allows individuals to transition from one healthy state to another
A directed graph representation of the health state modeled in the Markov model
In the NBS intervention cohort, two disease-modifying treatment options, namely nusinersen or gene therapy, were modeled to obtain the cost and outcome of the SMA patients screened
To generate QALY
Compare the incremental cost and QALY with the calculated incremental cost benefit ratio (ICER)
Cost-effectiveness of NBS and gene therapy
By using nusinersen or gene therapy to treat a pre-symptomatic SMA infant, compared with the clinically diagnosed late treatment of SMA, an additional 9.
In short, NBS plus gene therapy can improve the quality of life and longevity of SMA infants.
In short, NBS plus gene therapy can improve the quality of life and longevity of SMA infants.
Leave a message here
